Info

Origen Therapeutics is a biotechnology company developing product opportunities arising from the emerging field of avian transgenic animal technology. The company's mission is to become the leading developer of a novel class human immunotherapeutics known as fully human sequence polyclonal antibodies. These antibodies are expected to have significant advantages over monoclonal antibodies that currently are in great favor amongst developers of human therapeutics. Origen plans to create corporate alliances with biotechnology and large pharmaceutical companies for the commercialization of these products. Origen's business is characterized by:A broad-based technology platform offering a wide array of immuntherapeutic products. Products that address large market opportunities and important healthcare needs. A strong intellectual property position through exclusive license to issued and pending patents underpinning the company's technology platform. A management and scientific team with significant experience in the areas of avian transgenics, immunotherapeutics, and management of emerging biotechnology companies. Origen Therapeutics is developing a powerful, broad-based technology platform centered on the isolation, culture and genetic modification of avian embryonic cells. These cells have the capacity to differentiate into many other cell types including germ cells making them useful for introducing genetic modifications into chickens. Origen holds an exclusive license to issued patents covering certain gene transfer and targeting technologies that enables the genetic modification of these cells. Together, these and other technologies developed in house allow Origen to manipulate the avian genome in sophisticated and versatile ways, creating a powerful technology platform for development of human therapeutics.